YM178
Phase 3Small molecule
AstellasYM178 is one of 28 small molecule programs targeting Overactive Bladder. It is currently in Phase 3.
1
Indications
15
Total Trials
0
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
150 competitors in Overactive Bladder
#DrugCompanyPhaseTrials
1Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Botox
AbbViePhase 3
GSK1358820
GSKPhase 3
Tolterodine PR
PfizerPhase 3
Oxybutynin Chloride
Mylan Pharmaceuticals IncPhase 3
Vesicare
AstellasPhase 3
SPM 907
PfizerPhase 3
Onabotulinumtoxina 100 UNT
SStanford University
Phase 3
Standard Medication Therapy
QQing Yuan
Phase 3
Oxybutynin ER
FFar Eastern Memorial Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Overactive Bladder6 trials
Tics2 trials
Elderly1 trial
Renal Impairment1 trial
4 more indications
Interaction1 trial
Absorption1 trial
Fed1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YM178. EMBL-EBI & Wellcome Sanger Institute.
- [4]